These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 29439277)

  • 1. Inhibitors in Nonsevere Hemophilia A: What Is Known and Searching for the Unknown.
    Abdi A; Linari S; Pieri L; Voorberg J; Fijnvandraat K; Castaman G
    Semin Thromb Hemost; 2018 Sep; 44(6):568-577. PubMed ID: 29439277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging Issues in Diagnosis, Biology, and Inhibitor Risk in Mild Hemophilia A.
    Castaman G; Eckhardt C; van Velzen A; Linari S; Fijnvandraat K
    Semin Thromb Hemost; 2016 Jul; 42(5):507-12. PubMed ID: 27148839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonsevere hemophilia A: often overlooked, but not forgotten.
    Lim MY; Buckner TW
    Curr Opin Hematol; 2020 Sep; 27(5):295-301. PubMed ID: 32701616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A.
    Eckhardt CL; van Velzen AS; Peters M; Astermark J; Brons PP; Castaman G; Cnossen MH; Dors N; Escuriola-Ettingshausen C; Hamulyak K; Hart DP; Hay CR; Haya S; van Heerde WL; Hermans C; Holmström M; Jimenez-Yuste V; Keenan RD; Klamroth R; Laros-van Gorkom BA; Leebeek FW; Liesner R; Mäkipernaa A; Male C; Mauser-Bunschoten E; Mazzucconi MG; McRae S; Meijer K; Mitchell M; Morfini M; Nijziel M; Oldenburg J; Peerlinck K; Petrini P; Platokouki H; Reitter-Pfoertner SE; Santagostino E; Schinco P; Smiers FJ; Siegmund B; Tagliaferri A; Yee TT; Kamphuisen PW; van der Bom JG; Fijnvandraat K;
    Blood; 2013 Sep; 122(11):1954-62. PubMed ID: 23926300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
    Kubisz P; Plamenová I; Hollý P; Stasko J
    Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factor VIII therapy for hemophilia A: current and future issues.
    Aledort L; Ljung R; Mann K; Pipe S
    Expert Rev Hematol; 2014 Jun; 7(3):373-85. PubMed ID: 24717090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FVIII Immunogenicity-Bioinformatic Approaches to Evaluate Inhibitor Risk in Non-severe Hemophilia A.
    Hart DP
    Front Immunol; 2020; 11():1498. PubMed ID: 32849511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitors in nonsevere haemophilia A: outcome and eradication strategies.
    van Velzen AS; Eckhardt CL; Hart DP; Peters M; Rangarajan S; Mancuso ME; Smiers FJ; Khair K; Petrini P; Jiménez-Yuste V; Hay CR; van der Bom JG; Yee TT; Fijnvandraat K;
    Thromb Haemost; 2015 Jul; 114(1):46-55. PubMed ID: 25879247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitors in Hemophilia: Treatment Challenges and Novel Options.
    Barg AA; Livnat T; Kenet G
    Semin Thromb Hemost; 2018 Sep; 44(6):544-550. PubMed ID: 29232720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment Regimens with Bypassing Agents in Patients with Hemophilia A and Inhibitors: A Survey from the Italian Association of Hemophilia Centers (AICE).
    Coppola A; Franchini M; Castaman G; Santagostino E; Santoro C; Santoro RC; Morfini M; Di Minno G; Rocino A;
    Semin Thromb Hemost; 2018 Sep; 44(6):551-560. PubMed ID: 29723892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerance induction in hemophilia A animal models: battling inhibitors with antigen-specific immunotherapies.
    Adair P; Su Y; Scott DW
    Discov Med; 2013 May; 15(84):275-82. PubMed ID: 23725600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Molecular genetics of hemophilia A].
    De Brasi CD; Slavutsky IR; Larripa IB
    Medicina (B Aires); 1996; 56(5 Pt 1):509-17. PubMed ID: 9239887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemophilia A--from basic science to clinical practice.
    Klinge J; Ananyeva NM; Hauser CA; Saenko EL
    Semin Thromb Hemost; 2002 Jun; 28(3):309-22. PubMed ID: 12098093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of factor VIII concentrates on the immune system of patients with hemophilia.
    Mannucci PM
    Thromb Haemost; 1995 Jul; 74(1):437-9. PubMed ID: 8578501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitors in Patients with Congenital Bleeding Disorders Other Than Hemophilia.
    Franchini M; Marano G; Mengoli C; Piccinini V; Pupella S; Vaglio S; Liumbruno GM
    Semin Thromb Hemost; 2018 Sep; 44(6):595-603. PubMed ID: 29165739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune tolerance induction in patients with hemophilia A.
    Astermark J
    Thromb Res; 2011 Jan; 127 Suppl 1():S6-9. PubMed ID: 21056905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of inhibitor development in hemophilia A in 2016. A glimpse into the future?
    Franchini M; Lippi G
    Thromb Res; 2016 Dec; 148():96-100. PubMed ID: 27816852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of inhibitors in previously untreated patients with severe haemophilia A after exposure to a single intermediate purity factor VIII product.
    Yee TT; Williams MD; Hill FG; Lee CA; Pasi KJ
    Thromb Haemost; 1997 Sep; 78(3):1027-9. PubMed ID: 9308748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemophilia A inhibitor treatment: the promise of engineered T-cell therapy.
    Parvathaneni K; Abdeladhim M; Pratt KP; Scott DW
    Transl Res; 2017 Sep; 187():44-52. PubMed ID: 28651073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.